(Bloomberg) -- Novo Nordisk A/S’ best-selling diabetes and weight-loss drugs Ozempic and Wegovy appear to be associated with a higher risk of a rare form of vision loss, according to an analysis by doctors at Massachusetts Eye and Ear, a Harvard-affiliated hospital.Most Read from BloombergUS Allies Say China Is Developing Attack Drones for RussiaChina Can End Russia’s War in Ukraine With One Phone Call, Finland SaysBiden Struggles to Contain Pressure to Abandon Reelection BidHouse Democrats Cons
(Bloomberg) — Novo Nordisk A/S’ (NVO) best-selling diabetes and weight-loss drugs Ozempic and Wegovy appear to be associated with a higher risk of a rare form of vision loss, according to an analysis by doctors at Massachusetts Eye and Ear, a Harvard-affiliated hospital.
Most Read from Bloomberg
US Allies Say China Is Developing Attack Drones for Russia
China Can End Russia’s War in Ukraine With One Phone Call, Finland Says
Biden Struggles to Contain Pressure to Abandon Reelection Bid
